Bladder cancer in the EMPA-REG OUTCOME trial

Diabetologia

Volumn 60, Issue 12, 2017, Pages 2534-2535

  Kohler, Sven ^a   Lee, Jisoo ^a   George, Jyothis T ^a   Inzucchi, Silvio E ^b   Zinman, Bernard ^c  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Bladder cancer; Cancer; Empagliflozin; SGLT2 inhibitors; Type 2 diabetes

Indexed keywords

EMPAGLIFLOZIN; PLACEBO;

BLADDER CANCER; CANCER RECURRENCE; CLINICAL TRIAL; HUMAN; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

EID: 85029504449     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4430-0     Document Type: Letter

References (3)

1. Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J (2017) SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. https://doi.org/10.1007/s00125-017-4370-8
2. Boehringer Ingelheim (2016) Endocrinologic and metabolic drugs advisory committee briefing document. EMPA-REG OUTCOME® Trial. Available from www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM508423.pdf. Accessed 28 July 2017
3. Griffiths TRL (2013) Current perspectives in bladder cancer management. Int J Clin Pract 65:435–448